Therapeutic Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Autoimmune Disease Vaccines, Neurological Disease Vaccines, Cancer Vaccines, Infectious Disease Vaccines, And Other Products), By Technology (Autologous Vaccines and Allogeneic Vaccines), By Type of Therapy (Monotherapy and Combination Therapy), By Route of Administration (Intravenou
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationTherapeutic Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Autoimmune Disease Vaccines, Neurological Disease Vaccines, Cancer Vaccines, Infectious Disease Vaccines, And Other Products), By Technology (Autologous Vaccines and Allogeneic Vaccines), By Type of Therapy (Monotherapy and Combination Therapy), By Route of Administration (Intravenou
| Forecast Period | 2024-2028 |
| Market Size (2022) | USD 27.81 Billion |
| CAGR (2023-2028) | 9.68% |
| Fastest Growing Segment | Autologous Vaccines |
| Largest Market | North America |
Market Overview
Global Therapeutic Vaccines Market has valued at USD 27.81 Billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 9.68% through 2028.
Key Market Drivers
Increase in the Geriatric Population
The increase in the geriatric population is contributing to the rising demand for therapeutic vaccines due to several interconnected factors. As people age, their immune systems can weaken, making them more susceptible to various infections and diseases. Therapeutic vaccines offer a way to address these vulnerabilities and enhance immune responses among the elderly population. As individuals age, their immune systems undergo changes, commonly referred to as immunosenescence. This leads to a decline in immune responses and a reduced ability to fight off infections and diseases. Therapeutic vaccines can stimulate and boost immune responses, helping to counteract the weakened immune function in the elderly. Older adults are more vulnerable to infectious diseases such as influenza, pneumonia, and shingles. Therapeutic vaccines, including those specifically designed for older populations, can provide immunity against these infections, reducing the risk of severe illness and hospitalization. The elderly population is more likely to have chronic conditions such as diabetes, heart disease, and respiratory disorders. These conditions can exacerbate the impact of infections. Therapeutic vaccines can help prevent infections that could further strain the health of older adults with chronic illnesses.
Increasing Prevalence of Various Chronic Ailments
Chronic diseases, such as diabetes, cancer, cardiovascular diseases, and autoimmune disorders, pose significant health challenges and economic burdens worldwide. Therapeutic vaccines offer a potential avenue for addressing these challenges by providing innovative approaches to managing and treating chronic conditions. Many chronic diseases involve dysregulation of the immune system. Therapeutic vaccines can modulate the immune response to target specific components of the disease, potentially slowing down disease progression and improving outcomes.
Reducing Disease BurdenChronic diseases often require long-term management and treatment, placing a substantial burden on individuals, families, and healthcare systems. Therapeutic vaccines that can reduce disease severity, complications, and the need for frequent interventions can alleviate this burden.
Advances in personalized medicine have led to the development of therapeutic vaccines that are tailored to an individual's specific disease profile. These vaccines can target disease-specific antigens, offering a more precise and effective treatment approach. Therapeutic cancer vaccines aim to stimulate the immune system to recognize and attack cancer cells. They can be used alongside traditional treatments like chemotherapy and radiation, enhancing the body's ability to fight cancer and potentially improving survival rates. Therapeutic vaccines can be designed to suppress or regulate an overactive immune response, which is a characteristic of autoimmune disorders. These vaccines can help manage autoimmune conditions by restoring immune balance.
Growing Need for Effective Biologic Medications for Specific And Targeted Responses
Therapeutic vaccines, which are designed to treat or manage diseases rather than prevent them, offer a targeted approach to addressing specific medical conditions. This aligns with the broader trend towards personalized medicine, where treatments are tailored to individual patients' needs. Therapeutic vaccines are engineered to stimulate a specific immune response against disease-associated antigens. This precision allows for the direct targeting of disease cells, minimizing damage to healthy tissue. Therapeutic vaccines are a form of immunotherapy, which harnesses the body's immune system to fight diseases. As our understanding of immunology grows, the potential for using therapeutic vaccines to modulate immune responses becomes more apparent. Many chronic diseases, such as cancer and autoimmune disorders, require ongoing management and treatment.
Therapeutic vaccines offer a long-term solution by training the immune system to continually target and control disease cells. Therapeutic vaccines can be used in combination with other biologic medications, such as targeted therapies or checkpoint inhibitors, to enhance treatment efficacy. Targeted therapeutic vaccines have the potential to cause fewer side effects than broad-spectrum treatments. This is particularly beneficial for patients who may be unable to tolerate more aggressive therapies. Advances in biotechnology, including gene editing and synthetic biology, are enabling the creation of more sophisticated and effective therapeutic vaccines.
Increasing Purchasing Power of The Population
Higher purchasing power enables individuals to access a wider range of healthcare services, including advanced treatments like therapeutic vaccines. This leads to increased demand for innovative therapies that offer targeted and effective solutions. As people's economic status improves, they place a higher value on quality healthcare services. Therapeutic vaccines, which represent cutting-edge treatments, align with the desire for the best found at medical options. With increased purchasing power often comes greater awareness of health and well-being. Individuals are more likely to seek out preventive measures and advanced treatments like therapeutic vaccines to address health concerns proactively.
Therapeutic vaccines, being a form of advanced biologic medication, may have higher costs associated with their development and production. As purchasing power increases, individuals and healthcare systems are better equipped to afford these innovative treatments. Therapeutic vaccines often align with the concept of personalized medicine, where treatments are tailored to individual patients. The ability to access and afford such tailored treatments becomes more feasible with higher purchasing power.
Economic growth often results in a growing middle-class population with more discretionary income. This demographic segment is more likely to seek out and afford novel healthcare options, including therapeutic vaccines. In regions with higher purchasing power, individuals might have the means to travel to other countries for specialized medical treatments, including therapeutic vaccines, further driving demand. Economic empowerment can lead to increased investment in healthcare infrastructure and technology. This enables healthcare providers to offer advanced treatments like therapeutic vaccines, contributing to market growth.
Key Market Challenges
High Vaccine Cost
While therapeutic vaccines hold promise for treating various diseases, their development, production, and delivery often come with significant financial challenges that impact their accessibility and utilization. High vaccine costs can make therapeutic vaccines inaccessible to a significant portion of the population, especially in regions with limited healthcare resources or individuals with lower income levels. The cost barrier can exacerbate existing healthcare disparities, preventing marginalized or vulnerable populations from accessing potentially life-saving therapeutic vaccines. The high cost of therapeutic vaccines can strain healthcare systems and budgets, diverting resources from other essential medical services and treatments.
Lack Of Therapeutic Drug Availability
Therapeutic vaccines are a subset of biologic medications designed to treat specific diseases or conditions, and their successful development relies on having appropriate therapeutic drugs or targets found at for targeting immune responses. Therapeutic vaccines often rely on targeting specific disease-related antigens, proteins, or markers. If suitable therapeutic drugs for these targets are not found at, it becomes challenging to identify and validate effective vaccine candidates. Therapeutic vaccines often require reliable biomarkers to monitor treatment response and assess patient outcomes. The absence of specific therapeutic drugs or biomarkers can hinder the development and optimization of these vaccines. If therapeutic drugs that can effectively manage or treat the disease are not found at, the clinical efficacy of therapeutic vaccines may be limited, undermining their potential benefits.
Key Market Trends
Neoantigen Vaccines
Neoantigens are unique antigens expressed on cancer cells due to mutations. Neoantigen vaccines are designed to target these mutations, enabling the immune system to recognize and attack cancer cells specifically. These vaccines have shown promise in early-stage clinical trials. Neoantigens are immunogenic, meaning they can provoke a strong immune response. This makes them attractive targets for cancer immunotherapy. Neoantigen vaccines are tailored to each patient's unique tumor mutations, allowing for a personalized treatment approach. Neoantigen vaccines represent an exciting frontier in cancer immunotherapy. Their ability to harness the immune system's specificity to target unique cancer mutations holds the potential to revolutionize cancer treatment by providing tailored therapies that minimize damage to healthy tissue. As research continues to refine their development and clinical applications, neoantigen vaccines could play a significant role in advancing precision oncology and improving patient outcomes.
Novel Vaccine Delivery Platforms
Innovations in vaccine delivery platforms, such as nanoparticles, viral vectors, and RNA-based technologies, are enhancing the efficacy and precision of therapeutic vaccines, making them more attractive options for patients and healthcare providers. Nanoparticles can be designed to specifically target immune cells or tissues, enhancing the vaccine's effectiveness. Nanoparticles can protect vaccine components from degradation and enhance their stability during storage and transport. Controlled release of antigens from nanoparticles can lead to prolonged immune stimulation, potentially resulting in a stronger and more sustained immune response.
Segmental Insights
Product
Based on the product, the market is categorized into autoimmune disease vaccines, neurological disease vaccines, cancer vaccines, infectious disease vaccines, and other products. The autoimmune disease vaccine products hold the largest market share in the global therapeutic vaccines market. This growth can be attributed to the increasing number of patients diagnosed with type 1 diabetes and cancer. The significant growth in patients with these diseases is driving the demand for autoimmune disease vaccine products, which is expected to continue dominating the global therapeutic vaccines market throughout the forecast period.
Technology Insights
The global therapeutic vaccines market, categorized based on technology, comprises Autologous Vaccines and Allogeneic Vaccines. Autologous vaccines are projected to drive market growth throughout the forecast period. They are anticipated to contain unique or rare tumor antigens that result from mutational events. These vaccines target existing cancer cells and help prevent tumor recurrence following conventional cancer treatments such as surgery, radiation, or chemotherapy, which have successfully eliminated most or all of the cancer.
Regional Insights
Based on geography
the Global Therapeutic Vaccines Market is categorized into North America, Europe, Asia Pacific, South America, and MEA. The North American region currently holds the highest market share and is expected to continue dominating the Global Therapeutic Vaccines Market throughout the forecast period. This can be attributed to the increasing number of patients diagnosed with chronic diseases such as cancer and neurological disorders in this region. Additionally, the advanced healthcare system in North America contributes to this growth.The European preventive and therapeutic vaccine market holds the second position in terms of market size, following North America. The benefits from extensive research, and development conducted by multinational corporations, their deep expertise in vaccine production. With the increasing prevalence of diseases in both children and adults, the demand for preventive vaccines is expected to rise in the coming years. To meet this demand, major companies such as Pfizer, Merck, Sanofi, and Glaxo Smith Kline will play a key role in the future.
In the APAC preventive and therapeutic vaccine market, the increasing incidences of cancer and HIV cases are projected to drive the demand for vaccines, thereby boosting market growth. Factors such as the improvement of the healthcare sector, rising healthcare expenditure, and government initiatives are expected to have a significant impact on the adoption rates of vaccines. According to WHO estimates, the market holds immense potential with the introduction of new and improved preventive and therapeutic vaccines. China and India are anticipated to experience substantial growth over the next 10 years, driven by the growing prevalence of various infectious diseases and positive economic indicators.
Recent Developments
- April 2022A team atKing's College London reportedly made a groundbreaking discovery by using mRNAtechnology, similar to the Covid vaccines, to develop the world's first curefor heart attacks.
- March 2022TheNational Institute of Allergy and Infectious Diseases (NIAID), a part of theNational Institutes of Health (NIH), initiated a Phase 1 clinical trial toassess the efficacy of three experimental HIV vaccines based on a messenger RNA(mRNA) platform. NIAID is the sponsor of the study, known as HVTN 302, and thetrial is being conducted by the NIAID-funded HIV Vaccine Trials Network (HVTN)at the Fred Hutchinson Cancer Research Center in Seattle.
- On January 30, 2019,Merck announced that their investigational pneumococcal conjugate vaccine,V114, has been granted Breakthrough Therapy Designation by the US FDA for theprevention of invasive pneumococcal disease (IPD) in pediatric patients aged 6weeks to 18 years, caused by the vaccine serotypes.
Key Market Players
- Agenus Inc.
- Argos Therapeutic Inc.
- Celldex Therapeutic Inc. (Avant Immunotherapeutics, Inc.)
- Dendreon Corp (Sanpower Group Co., Ltd.)
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Novartis AG
- Pfizer, Inc.
- Phio Pharmaceuticals Corp.
- INOVIO Pharmaceuticals
| By Product | By Technology | By Type of Therapy | By Route of Administration | By Distribution Channel | By Region |
|
|
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy